Charles Schwab Investment Management Inc. Increases Stock Holdings in Prestige Consumer Healthcare Inc. $PBH

Key Points

• Charles Schwab Investment Management Inc. has increased its stake in Prestige Consumer Healthcare Inc. by 1.0%, acquiring an additional 6,370 shares to reach a total of 642,390 shares, valued at approximately $55.2 million.
• The company's stock recently saw a modest increase of 0.7%, with a current market cap of $3.20 billion and significant institutional ownership at 99.95%.
• Prestige Consumer Healthcare reported a loss in Q2 earnings, with an EPS of $0.95, falling short of expectations, while revenue declined 6.6% year-over-year.

Charles Schwab Investment Management Inc. lifted its stake in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 1.0% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 642,390 shares of the company's stock after acquiring an additional 6,370 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 1.30% of Prestige Consumer Healthcare worth $55,226,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently made changes to their positions in the stock. Cerity Partners LLC raised its position in shares of Prestige Consumer Healthcare by 3.7% during the first quarter. Cerity Partners LLC now owns 3,666 shares of the company's stock worth $315,000 after acquiring an additional 132 shares during the last quarter. KBC Group NV raised its position in shares of Prestige Consumer Healthcare by 7.4% during the first quarter. KBC Group NV now owns 2,199 shares of the company's stock worth $189,000 after acquiring an additional 151 shares during the last quarter. McIlrath & Eck LLC grew its stake in Prestige Consumer Healthcare by 19.1% during the fourth quarter. McIlrath & Eck LLC now owns 959 shares of the company's stock worth $75,000 after purchasing an additional 154 shares during the period. Xponance Inc. grew its stake in Prestige Consumer Healthcare by 5.5% during the first quarter. Xponance Inc. now owns 3,766 shares of the company's stock worth $324,000 after purchasing an additional 196 shares during the period. Finally, Summit Investment Advisors Inc. grew its stake in Prestige Consumer Healthcare by 4.2% during the fourth quarter. Summit Investment Advisors Inc. now owns 5,182 shares of the company's stock worth $405,000 after purchasing an additional 211 shares during the period. 99.95% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

PBH has been the subject of several recent analyst reports. Royal Bank Of Canada raised Prestige Consumer Healthcare to a "hold" rating in a research note on Thursday, May 8th. Wall Street Zen cut Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a research note on Saturday, August 9th. Finally, Canaccord Genuity Group decreased their target price on Prestige Consumer Healthcare from $105.00 to $100.00 and set a "buy" rating for the company in a research note on Friday, August 8th. Three equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $93.33.

Prestige Consumer Healthcare Stock Up 0.1%

Prestige Consumer Healthcare stock traded up $0.0650 during mid-day trading on Tuesday, reaching $64.9350. The stock had a trading volume of 345,392 shares, compared to its average volume of 387,991. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.99 and a current ratio of 4.38. Prestige Consumer Healthcare Inc. has a fifty-two week low of $62.95 and a fifty-two week high of $90.04. The stock's 50-day simple moving average is $76.85 and its 200-day simple moving average is $81.54. The firm has a market capitalization of $3.20 billion, a PE ratio of 15.26, a price-to-earnings-growth ratio of 2.05 and a beta of 0.43.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $0.95 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.01 by ($0.06). The company had revenue of $249.53 million for the quarter, compared to analysts' expectations of $260.71 million. Prestige Consumer Healthcare had a net margin of 19.02% and a return on equity of 12.69%. The firm's quarterly revenue was down 6.6% on a year-over-year basis. During the same period in the previous year, the firm earned $0.90 EPS. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS. On average, sell-side analysts forecast that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current fiscal year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.